Mendus provides business update and outlook for vididencel program

Press Release Stockholm, Sweden, March 12, 2024 ADVANCE II Phase 2 trial data provide basis for late-stage development of lead product vididencel in acute myeloid leukemiaRegistration trial...

Related Keywords

Sweden ,Australia ,United States ,Netherlands ,Stockholm ,American ,Australian ,Erik Manting ,Lymphoma Group ,American Society For Hematology ,Northx Biologics ,Business Update ,American Society ,Australian Leukemia ,Inderes Event Studio ,Nasdaq Stockholm ,Markets ,